|
Volumn 5, Issue 4, 2006, Pages 277-278
|
The GERD market
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALEMCINAL;
ANTACID AGENT;
ATI 7505;
BACLOFEN;
CISAPRIDE;
DDP 733;
DEXLOXIGLUMIDE;
DOMPERIDONE;
ERYTHROMYCIN;
FAMOTIDINE;
METOCLOPRAMIDE;
MITEMCINAL;
OMEPRAZOLE;
PRODRUG;
PROTON PUMP INHIBITOR;
RANITIDINE;
SEROTONIN 4 AGONIST;
SORAPRAZAN;
TEGASEROD;
TUMS;
UNCLASSIFIED DRUG;
XP 19986;
BARRETT ESOPHAGUS;
BEHAVIOR MODIFICATION;
CENTRAL NERVOUS SYSTEM DISEASE;
CHRONIC DISEASE;
CLINICAL FEATURE;
CLINICAL TRIAL;
DAYTIME SOMNOLENCE;
DISEASE CLASSIFICATION;
DISEASE SEVERITY;
DRUG COST;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG TOLERABILITY;
ESOPHAGEAL ADENOCARCINOMA;
GASTROESOPHAGEAL REFLUX;
HEALTH CARE COST;
HEART ARRHYTHMIA;
HEARTBURN;
HUMAN;
INCIDENCE;
LIFESTYLE;
NOTE;
PRIORITY JOURNAL;
SLEEP DISORDER;
STOMACH ACID SECRETION;
TACHYPHYLAXIS;
UNSPECIFIED SIDE EFFECT;
GASTROESOPHAGEAL REFLUX;
HISTAMINE H2 ANTAGONISTS;
HUMANS;
PROTON PUMPS;
SEROTONIN AGONISTS;
|
EID: 33645464961
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2011 Document Type: Note |
Times cited : (3)
|
References (7)
|